Featured Research

from universities, journals, and other organizations

Scientists Combine Therapeutic Cloning, Embryonic Stem Cells, And Gene Defect In Mice

Date:
March 11, 2002
Source:
Whitehead Institute For Biomedical Research
Summary:
While the promise of nuclear transplantation therapy, commonly referred to as "therapeutic cloning," has given hope to patients, like Christopher Reeve, and excited the research community and the public, it has never been successfully demonstrated. Now, scientists from the Whitehead Institute for Biomedical Research have used a mouse model to establish for the first time that a combination of nuclear transplantation, gene therapy, and embryonic stem cell differentiation can be used to create custom-tailored cellular therapies for genetic disorders.

While the promise of nuclear transplantation therapy, commonly referred to as "therapeutic cloning," has given hope to patients, like Christopher Reeve, and excited the research community and the public, it has never been successfully demonstrated. Now, scientists from the Whitehead Institute for Biomedical Research have used a mouse model to establish for the first time that a combination of nuclear transplantation, gene therapy, and embryonic stem cell differentiation can be used to create custom-tailored cellular therapies for genetic disorders.

Related Articles


The work is a result of a collaboration between Whitehead Member Rudolf Jaenisch’s lab and Whitehead Fellow George Daley’s lab and will be published as two companion papers on the Cell web site on Friday, March 8, 2002.

The Whitehead researchers joined forces to work on a problem that until now has proven difficult to overcome. Scientists have been able to use nuclear transfer to create embryonic stem cells and differentiate them in culture to create many different cell types, including muscle, neurons, and hematopoietic stem cells, which are the precursors to all immune and blood cells. But, they have never shown that the cells created in culture could be reintroduced into an animal to treat a disease.

Combining their independent research interests, the Jaenisch and Daley labs used skin cells from a mouse, which was completely immune deficient, to create a cellular therapy that was able to partially restore immune function in the mouse. "Though the immune system wasn’t completely restored, there was enough improvement to predict that a comparable result in humans would translate into a significant clinical benefit," says Daley.

"This is a proof-of-principle experiment, which shows that nuclear transplantation therapy may be possible for human application. Furthermore, it shows that gene therapy can be incorporated into the approach to correct genetic mutations in defective cells without affecting the germ line," added Jaenisch.

Essential Collaboration

Postdoctoral fellowWilliam Rideout and graduate student Konrad Hochedlinger, both of the Jaenisch lab, used the nuclear transfer procedure to remove the nucleus, which contains the DNA of a cell, from an egg and replace it with the nucleus from a skin cell of an adult mouse with a genetic immune deficiency. In this procedure, the egg resets the developmental clock of the adult nucleus and the reprogrammed cell starts developing into an embryo that is genetically identical to the donor cell.

At the stage when the embryo develops into a hollow ball of approximately a hundred cells, called a blastocyst, it contains a nub composed of embryonic stem (ES) cells that have the potential to become any cell in the body. The ES cells from the blastocyst were isolated and the genetic defect causing the immune deficiency was corrected by gene therapy.

These corrected embryonic stem cells, however, couldn’t be successfully transplanted into the adult mouse to treat the immune disorder. For some reason, adult mice reject transplants of blood cell precursors derived from embryonic stem cells in culture.

"While embryonic stem cells could be induced to form hematopoietic cells in culture, these cells wouldn’t reliably generate the blood and immune system when transplanted into mice. For the last 15 years, engrafting mice with blood derived from embryonic stem cells has been the Holy Grail of the field," explained Daley.

Michael Kyba, a postdoctoral fellow in the Daley lab, found a way to achieve this goal by inserting a gene called HoxB4 that stimulates blood cell proliferation. The HoxB4 modified cells generated hematopoietic stem cell precursors that could be successfully transplanted into adult mice.

With this newfound ability, the researchers applied the same strategy to the genetically corrected embryonic stem cells made from the immunodeficient mouse. Remarkably, these genetically corrected cells were able to partially rescue the immune systems of mice suffering from complete immune deficiency.

Challenges

In principle, this approach might be useful some day for treating human patients with immune deficiency (ie. "bubble boy disease") or be applied to a host of other genetic diseases that can be corrected by cell transplantation. Embryonic stem cells can form any tissue in the body, including neurons, muscle cells of the heart, and pancreatic beta cells, which produce insulin.

In addition to the potential broad range of use, nuclear transplantation therapy to create embryonic stem cells has many benefits—the creation of cells that are genetically matched to the patient, the repair of genetic defects within cells to treat or cure inherited diseases, and the possibility of growing embryonic stem cells in culture for continued therapy as needed.

"Before the potential of nuclear transplantation therapy can be realized, much more research about the basic biology of stem cells has to done," says Daley. Unexpectedly, the researchers confronted interesting biological principles, which appear to be related to a fundamental difference between adults cells and cells derived from embryonic stem cells, even when the two types of cells are genetically identical. "While these results show nuclear transplantation therapy can work in principle, there are technical issues that we are working on now," explained Jaenisch.

Funding

The work from the Daley lab was supported by grants from the NIH, the National Science Foundation, MIT Biotechnology Process Engineering Center, the Canadian Institutes of Health Research, and the Alberta Heritage Foundation for Medical Research.

The work from the Jaenisch lab was supported by Boehringer Ingelheim Fonds and the National Cancer Institute.


Story Source:

The above story is based on materials provided by Whitehead Institute For Biomedical Research. Note: Materials may be edited for content and length.


Cite This Page:

Whitehead Institute For Biomedical Research. "Scientists Combine Therapeutic Cloning, Embryonic Stem Cells, And Gene Defect In Mice." ScienceDaily. ScienceDaily, 11 March 2002. <www.sciencedaily.com/releases/2002/03/020311075845.htm>.
Whitehead Institute For Biomedical Research. (2002, March 11). Scientists Combine Therapeutic Cloning, Embryonic Stem Cells, And Gene Defect In Mice. ScienceDaily. Retrieved November 28, 2014 from www.sciencedaily.com/releases/2002/03/020311075845.htm
Whitehead Institute For Biomedical Research. "Scientists Combine Therapeutic Cloning, Embryonic Stem Cells, And Gene Defect In Mice." ScienceDaily. www.sciencedaily.com/releases/2002/03/020311075845.htm (accessed November 28, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, November 28, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com
Experimental Ebola Vaccine Shows Promise In Human Trial

Experimental Ebola Vaccine Shows Promise In Human Trial

Newsy (Nov. 27, 2014) — A recent test of a prototype Ebola vaccine generated an immune response to the disease in subjects. Video provided by Newsy
Powered by NewsLook.com
Pet Dogs to Be Used in Anti-Ageing Trial

Pet Dogs to Be Used in Anti-Ageing Trial

Reuters - Innovations Video Online (Nov. 26, 2014) — Researchers in the United States are preparing to discover whether a drug commonly used in human organ transplants can extend the lifespan and health quality of pet dogs. Video provided by Reuters
Powered by NewsLook.com
Today's Prostheses Are More Capable Than Ever

Today's Prostheses Are More Capable Than Ever

Newsy (Nov. 26, 2014) — Advances in prosthetics are making replacement body parts stronger and more lifelike than they’ve ever been. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins